Remove the target deconvolution bottleneck
The Retrogenix Cell Microarray Technology is ideally suited to target deconvolution. Specifically, it is used to identify the primary targets of large or small molecules that display a desired biological or clinical effect. This ranges from uncovering the primary target of antibodies or small molecule compounds identified by phenotypic screening, right through to marketed drugs where the mechanism of action has not been fully elucidated.
Given that antibody targets are predominantly plasma membrane proteins, and that antibodies require no direct labelling, our microarray technology is used extensively for the antibody target deconvolution.
- novel, druggable targets
- receptors targeted by phenotypic molecules (antibodies, ScFvs, Fc-fusion proteins etc)
- disease-specific antigens by direct screening of patient plasma samples